Gain Therapeutics, Inc. (GANX)

In July 2025, Gain Therapeutics announced and priced a public offering, generating approximately $7.1 million in net proceeds. In September 2025, the company received Australian approval for a Phase 1b dosing extension for GT-02287 and commenced its GT-02287 Phase 1b extension study in individuals with Parkinson's Disease. In October 2025, Gain Therapeutics presented initial positive data from its Phase 1b clinical study of GT-02287 in Parkinson's patients, suggesting a disease-slowing effect. In November 2025, the company reported its financial results for the third quarter of 2025, including a net loss of $0.15 per share and cash and cash equivalents of $8.8 million as of September 30, 2025, and presented preclinical GT-02287 data at Neuroscience 2025. Overall, the stock price of GANX has increased by 56.04% from November 25, 2024, to November 24, 2025.

The demand for Gain Therapeutics' products and services is not subject to typical consumer-driven seasonality. Demand for their future drug products will primarily be driven by the prevalence of the diseases they aim to treat, the efficacy and safety profile of their therapies, and regulatory approvals. The current search results do not indicate any seasonality in the demand for Gain Therapeutics' drug candidates or their drug discovery platform.

Gain Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing precision therapeutics for neurodegenerative and rare diseases, leveraging its Magellan platform to identify novel allosteric binding sites and discover small molecules. The company operates in the Medical sector, specifically in the Drugs and Pharmaceutical Products industry, with a focus on developing small molecule therapeutics for lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. Its lead candidate, GT-02287, is being developed for GBA1 Parkinson's disease, while GT-022 is in development for Gaucher disease. The company also has drug candidates in discovery, research, and preclinical stages for conditions such as dementia with Lewy bodies, Alzheimer's disease, and solid tumors.

Gain Therapeutics operates geographically in Switzerland, Spain, the United States, and Australia. The company is headquartered in Geneva, Switzerland, with research operations located in Massachusetts, and its corporate office is in Bethesda, Maryland.

Gain Therapeutics has maintained a generally positive brand reputation, particularly within the analyst community, receiving a consensus rating of "Moderate Buy". Positive clinical data from the Phase 1b study for GT-02287 in Parkinson's patients and regular presentations at scientific conferences have contributed to its reputation. Consistent "Buy" recommendations from financial firms also indicate a favorable view. The overall news sentiment score for Gain Therapeutics is 0.99, indicating a neutral to slightly positive perception.

Gain Therapeutics is primarily owned by retail investors, who hold 84.36% of the company's shares. Institutional shareholders own approximately 11.97% to 12.36% of the stock, while insiders hold between 3.61% and 7.18%. The largest individual shareholder is Khalid Islam, owning 2.58% of the company. Major institutional owners include Jones Financial Companies LLLP, DME Capital Management, LP, Vanguard Group Inc, Citadel Advisors LLC, Geode Capital Management LLC, Cambridge Investment Research Advisors Inc, Marshall Wace LLP, and Morgan Stanley.